Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SWIPE: Switch Maintenance Pembrolizumab in NSCLC
NCT02705820Phase 2Completed
- Sponsor
- Bank of Cyprus Oncology Centre
- Start
- Apr 2016
- Primary completion
- May 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Bank of Cyprus Oncology Centre. Primary endpoint: Immune Related Progression Free Survival at 1 year. Started Apr 2016; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02705820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02705820.